Philippe A Gallay Selected Research

alisporivir

1/2015	The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.
1/2013	Profile of alisporivir and its potential in the treatment of hepatitis C.
10/2012	Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
4/2008	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philippe A Gallay Research Topics

Disease

14	Infections 01/2021 - 12/2006
3	Chronic Hepatitis C 10/2015 - 06/2014
3	Virus Diseases (Viral Diseases) 10/2015 - 02/2008
3	Hepatitis C 10/2014 - 01/2013
2	HIV Infections (HIV Infection) 01/2020 - 01/2017
2	Coinfection 01/2016 - 01/2015
2	Fibrosis (Cirrhosis) 01/2015 - 01/2013
1	COVID-19 01/2021
1	Body Weight (Weight, Body) 01/2020
1	Neoplasms (Cancer) 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2018
1	Reinfection 01/2016
1	Liver Neoplasms (Liver Cancer) 01/2015
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2015
1	Hyperbilirubinemia 01/2013
1	Rupture 10/2012
1	Viremia 10/2012
1	Vesicular Stomatitis 05/2011
1	Human Influenza (Influenza) 05/2011
1	Herpes Simplex 07/2010

Drug/Important Bio-Agent (IBA)

11	Antiviral Agents (Antivirals)IBA 01/2021 - 02/2008
4	Cyclophilins (Cyclophilin)IBA 01/2016 - 10/2012
4	alisporivirIBA 01/2015 - 04/2008
3	Pharmaceutical PreparationsIBA 01/2020 - 10/2014
3	Proteins (Proteins, Gene)FDA Link 10/2014 - 12/2006
2	astodrimerIBA 01/2021 - 01/2021
2	VaccinesIBA 01/2018 - 01/2017
2	InterferonsIBA 10/2014 - 06/2014
2	Peptides (Polypeptides)IBA 05/2011 - 02/2008
1	remdesivirIBA 01/2021
1	tenofovir alafenamideIBA 01/2020
1	Drug CombinationsIBA 01/2020
1	NF-kappa B (NF-kB)IBA 01/2019
1	CytokinesIBA 01/2019
1	ChemokinesIBA 01/2019
1	STG-175IBA 01/2016
1	ImmunophilinsIBA 10/2015
1	Molecular Probes (Molecular Probe)IBA 10/2015
1	Peptidylprolyl Isomerase (Prolyl Isomerase)IBA 10/2015
1	Human immunodeficiency virus 1 p16 proteaseIBA 01/2015
1	Nelfinavir (Viracept)FDA Link 01/2015
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2015
1	daclatasvirIBA 01/2015
1	Interferon-alpha (Interferon Alfa)IBA 01/2013
1	Anti-Infective Agents (Microbicides)IBA 11/2012
1	SyndecansIBA 07/2010
1	LipidsIBA 02/2008

Therapy/Procedure

3	Therapeutics 01/2019 - 01/2013
1	Aftercare (After-Treatment) 01/2021
1	Art Therapy 01/2019
1	Oral Administration 01/2019
1	Duration of Therapy 11/2013